Four Finalists Selected for BioWest 2010 Venture Showcase Competition, Presenting Life-Changing Technologies

DENVER--()--Cutting-edge development of a universal influenza vaccine, an innovative hybrid peptide manufacturing process, groundbreaking algae production system for wastewater treatment, and a revolutionary nontoxic surface treatment to control the growth of bacteria comprise the four finalists in this year’s BioWest Venture Showcase competition sponsored by Dorsey & Whitney and the Metro Denver Economic Development Corporation. The announcement is made by Holli Baumunk, President and CEO, Colorado BioScience Association (CBSA).

“By focusing on new therapies and vaccines targeting common diseases, creating systems and devices to fix problems and finding ways to more easily treat wastewater, the four finalists chosen for this year’s BioWest Venture Showcase are all on the frontline in making the world a better place,” Baumunk says. “The four finalists were selected from a group of 19 that will present at the BioWest Venture Showcase on Wednesday, September 29 from 1:00-2:30 p.m. at Denver’s Grand Hyatt. The winner will receive the $7,500 Dorsey & Whitney Venture Showcase award at the CBSA’s Annual Awards Dinner on the same day.”

To attend the Venture Showcase presentations and Annual Awards Dinner at BioWest, visit http://www.BioWestConference.com.

An overview of each finalist follows:

  • AmideBio (Boulder, CO) is a company in the business of improvement of human health by providing low cost and efficient manufacturing of peptides for the research and development markets. The Company’s proprietary hybrid manufacturing process also enables small scale cGMP manufacturing for clinical trials and the development of generic peptide therapeutics. In order to make progress against certain diseases and conditions, such as Alzheimer’s, it is necessary to be able to cost-effectively produce large quantities of peptides for research and development use, and ultimately therapeutic purposes. Current peptide synthesis technology is unable to produce certain peptides at an acceptable cost, or at all. AmideBio’s proprietary technology enables very cost-effective production of peptides and thus is a key enabling technology for development of new therapeutics for diseases for which there are currently limited or no good treatment options. Visit, http://www.amidebio.com.
  • BioVantage: (Golden, CO) In response to escalating water scarcity and the undeniable water/energy nexus, BioVantage is developing cost-effective, sustainable, “green” solutions for wastewater reclamation. Comprised of patent-pending technology and processes, BioVantage’s algae production system produces proprietary algae consortia for use in wastewater lagoons to accelerate natural remediation. This allows a greater degree of reuse of one of our planet’s most valuable and scarce resources, water. Visit, http://www.biovantageresources.com.
  • PeptiVir, Inc. (Aurora, CO) is an early stage biopharmaceutical company focused on the development and commercialization of a conformationally-constrained, synthetic peptide-based vaccine platform for the prevention of viral diseases. PeptiVir’s lead product, PVI-1000, has the potential to be a “universal” influenza vaccine wherein one or two administrations could lead to sustained protection against multiple seasonal and pandemic strains. This is in contrast to existing influenza vaccines that must be generated and administered yearly and induce antibodies that provide protection only against that year’s seasonal flu strains. Unlike other universal vaccine strategies that are being investigated and that focus on inducing cell-mediated immunity, PVI-1000 is predicted to work by inducing cross-reactive antibodies that would protect against multiple influenza virus strains, a prediction that should be readily confirmed in humans by examining the biological activity of the antibodies produced following vaccination.
  • Sharklet Technologies, Inc. (Aurora, CO) is a life sciences company that has engineered a revolutionary surface product called Sharklet. Sharklet is the first non-toxic, long-lasting and no-kill surface used to control the growth of bacteria. Sharklet is a patented surface technology comprised of millions of raised, microscopic features arranged in distinct diamond shapes to form a continuous pattern. Laboratory tests show that the Sharklet micro-pattern disrupts several critical microbial colonizing processes that are necessary for bacteria to develop into a disease-causing biofilm. In tests simulating an ambient hospital environment, the Sharklet patterned surface has shown to significantly reduce survival and touch transfer of bacteria. Until the advent of Sharklet, kill strategies including antibiotics, disinfectants and biocides have been the primary weapons to control bacterial growth. These kill strategies and their overuse has led to increased bacterial resistance, causing harm to people and the environment. Visit, http://www.sharklet.com.

As previously released, this year's CBSA Awards Dinner at BioWest will be keynoted by Colorado State University Animal-Science Professor Dr. Temple Grandin, whose HBO made-for-cable biopic just swept the Prime Time Emmy® Awards with five major and two creative arts award wins for her inspiring life story as a renowned animal scientist and autism activist.

Baumunk says, “BioWest is the region’s preferred venue for visiting with researchers about their newest discoveries and meeting founders of the area’s most innovative and promising bioscience start-up companies. Dr. Grandin, whose work is a prime example of the important research being done in Colorado, headlines an impressive lineup of speakers during the BioWest Conference, and we are all looking forward to her awards dinner keynote."

Additional national and international speakers confirmed for BioWest 2010 include:

  • September 29th Founder’s Breakfast: “Key Steps to Moving Colorado’s Bioscience Industry Forward” Tom Warwick, District Director, FDA Denver District will discuss how the changes in the FDA will impact the bioscience industry in Colorado.
  • September 29th Keynote Luncheon: “Health Care In Transition: The Outlook on What the Industry Should Expect” Jim Greenwood, President and CEO, Biotechnology Industry Association (BIO) and Mark Leahey, President and CEO, Medical Device Manufacturers Association (MDMA) discuss the recent health care reform and the role of the industry.
  • September 30th Grand Finale Luncheon: “The Year 2020 and the Role of the Venture Capitalist” Mark Heesen, President, National Venture Capital Association will present on how the financial constraints over the last few years has impacted the role of the VC and where he sees the future of the VC.

About Colorado BioScience Association

The CBSA supports the economic development of Colorado through the creation of a premier bioscience cluster within the state. Representing more than 400 members, the CBSA facilitates growth of the bioscience industry in Colorado through advocacy, representation and service. For more information about Colorado's dynamic bioscience cluster, visit the CBSA at http://www.cobioscience.com.

CBSA also is found on these social media sites:

Twitter: http://twitter.com/COBioscience

LinkedIn Group: http://www.linkedin.com/groups?about=&gid=98468&trk=anet_ug_grppro

Facebook Fan Page: http://www.facebook.com/ColoradoBioScienceAssociation

News Feed: http://coloradobio.blogspot.com

YouTube Channel: http://www.youtube.com/COBioscience

About Dorsey & Whitney LLP

Dorsey is a business law firm applying a business perspective to our clients' needs and committing to help our clients maintain that competitive edge. Dorsey's corporate lawyers serve clients ranging from start-ups to multinational corporations in a variety of matters including financings, M&A and joint ventures, regulatory, and general corporate matters. Dorsey represents numerous medical device, healthcare and other technology companies. Dorsey's patent lawyers combine their expertise in patent law and business acumen with their solid technical backgrounds to provide clients the advice they need on the most effective methods for protecting their technology and assisting them in patent portfolio strategic issues, patent preparation, prosecution, licensing and related activities in patent offices in the U.S. and around the world.

About Metro Denver Economic Development Corporation

The Metro Denver Economic Development Corporation (Metro Denver EDC), an affiliate of the Denver Metro Chamber of Commerce, is the nation’s first and only truly regional economic development entity in which many area economic development groups have joined together to represent, and further, the interests of an entire region. Our partners include 70 cities, counties, and economic development organizations in the seven-county Metro Denver and two-county Northern Colorado region. Visit: http://www.metrodenver.org.

Contacts

Colorado BioScience Association
Leah Kientz, 303-592-4088
Director, Public Policy & Programs
lkientz@cobioscience.com
http://www.cobioscience.com
or
Absolutely Public Relations
Maggie Chamberlin Holben, APR, 303-984-9801
maggie@absolutelypr.com
http://www.absolutelypr.com

Release Summary

Four finalists were selected from a group of 19 that will present at the BioWest Venture Showcase on Wednesday, September 29 from 1:00-2:30 p.m. at Denver’s Grand Hyatt.

Contacts

Colorado BioScience Association
Leah Kientz, 303-592-4088
Director, Public Policy & Programs
lkientz@cobioscience.com
http://www.cobioscience.com
or
Absolutely Public Relations
Maggie Chamberlin Holben, APR, 303-984-9801
maggie@absolutelypr.com
http://www.absolutelypr.com